Guidance. Clarity. Direction.

Carter, DeLuca & Farrell LLP, a leader in intellectual property law, provides cost-effective services to clients from around the world, protecting innovations in a wide range of technologies.

Throughout the phases of product or brand development, we form a critical part of our clients’ development teams to provide preparation, prosecution and clearance services to maximize protection while navigating through freedom-to-operate challenges. We also provide extensive IP due diligence services and IP asset assimilation to help our clients achieve their business objectives.

Search Attorneys

Events

Nov
30 – 30
2019
COMPEL CEOs 7th Annual Business & Economic Summit AttendingCarter DeLuca will be represented at the COMPEL CEOs 7th Annual Business & Economic Summit on October 30, 2019 at The Heritage...

CAFC Update

FRAUNHOFER-GESELLSCHAFT v. SIRIUS XM RADIO INC. October 17, 2019

Fraunhofer sued Sirius alleging infringement of claims of four of Fraunhofer’s patents. Fraunhofer and a third party, WorldSpace International Network Inc., entered into an exclusive license agreement (“the Master Agreement”) related to Fraunhofer’s multicarrier modulation technology. Sirius sought to use Fraunhofer’s technology and because Fraunhofer had already granted an exclusive license to WorldSpace, Sirius entered into a...

Fraunhofer sued Sirius alleging infringement of claims of four of Fraunhofer’s patents. Fraunhofer and a third party, WorldSpace International Network Inc., entered into...

HZNP MEDICINES LLC v. ACTAVIS LABORATORIES UT, INC October 10, 2019

The patents-at-issue generally relate to methods and compositions for topically treating osteoarthritis with a diclofenac salt and dimethyl sulfoxide and are listed in the FDA’s Orange Book for Horizon’s PENNSAID® 2% product. Actavis sought to market a generic version of PENNSAID 2% and filed an Abbreviated New Drug Application (“ANDA”) that included a certification that the patents-at-issue...

The patents-at-issue generally relate to methods and compositions for topically treating osteoarthritis with a diclofenac salt and dimethyl sulfoxide and are listed in...

B.E. TECHNOLOGY, L.L.C. v. FACEBOOK, INC. October 9, 2019

B.E. Technology filed suit accusing Facebook of infringing certain claims U.S. Patent 6,628,314 relating to methods and apparatus for providing an automatically upgradeable software application that includes targeted advertising. Approximately a year into the case, Facebook filed multiple petitions for inter partes review of the asserted claims and the district court stayed its proceedings pending the out-come of the Board’s...

B.E. Technology filed suit accusing Facebook of infringing certain claims U.S. Patent 6,628,314 relating to methods and apparatus for providing an automatically upgradeable software...